Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,194.7
21.8 (0.69%)

 

  • STI Straits Times Index
    3,194.7
    21.8 (0.69%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,567.3
    4.2 (0.27%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,994.1
    348.7 (1.31%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,915.7
    -8.7 (-0.30%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,424.8
    33.0 (0.14%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,139.4
    -40.7 (-0.66%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,137.3
    31.7 (1.51%)
    Index delayed 20 minutes
  • XAO XAO
    6,810.8
    -42.4 (-0.62%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 865.4M
  • Value: 1,189.2M
  • Rise: 151
  • Fall: 134
  • Unch: 541

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.179+0.012
Golden Agri-Res0.220-0.005
YZJ Shipbldg SGD1.090+0.010
Tritech0.024+0.001
GSS Energy0.084+0.006
Mapletree Com Tr2.280-0.050
SingTel3.390+0.030
CapitaMall Trust2.460-0.040
Ascendas Reit2.990-0.020
Genting Sing0.935+0.015

World Indices

World Indices
Name Last Change
Nasdaq 8,654.1 +37.9
HSI 26,994.1 +348.7
HSCEI 10,614.8 +112.2
Jakarta 6,139.4 -40.7
Nikkei 225 23,424.8 +33.0
SSE Comp 2,915.7 -8.7
Shanghai A 3,055.2 -9.1
Shanghai B 242.7 -1.4
PSE Comp 0.0
KOSPI 2,137.3 +31.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Suntar Eco-City^ SUNTAR ECO-CITY LIMITED
Quotes 10 Minutes Delayed. Updated at 12 Dec 2019 12:45
Last (SGD): 0.300 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 0.300
Buy Price 0.270 Sell Price 0.300
Buy Volume ('000) 34.4 Sell Volume ('000) 1.0
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.04265 Trailing EPS (SGD) e -0.03952 NAV (SGD) b 0.2652
PE a - Trailing PE f - Price / NAV b 1.1312
Dividend (SGD) d - Cash In Hand (SGD) g 0.1242 Issued & Paid-up Shares c 62,760,000
Dividend Yield (%) d - Price / Cash In Hand g 2.415 Treasury Shares h -
Beta - 75 Daysi 0.092 R-Squared - 75 Days(%)i 2.71 Market Cap (M) 18.828
Beta - 500 Daysi -0.401 R-Squared - 500 Days (%)i 0.22 Enterprise Value (M) 2.689
Piotroski F Score 4 Exchange Code BKZ Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 129.4395 6-Month VWAP 0.256 Free Float (%) -
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification China / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 20 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Suntar Eco-City^ SGX 18.828 - - 1.1312 -
Industry Biotechnology SGX 1,986.917 7.338 9.597 0.6937 4.748
China SGX 635.822 23.749 51.207 0.8027 3.435
Medical & Biotechnology SGX 984.454 22.413 23.192 1.3720 1.894
Local Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Local Peer QT Vascular SGX 4.471 0.111 - 0.2985 -
Global Peer AMGEN INC NASDAQ 139,044.998 16.565 17.236 12.7249 2.391
Global Peer CSL ASX 126,715.407 47.230 47.230 16.9334 0.950
Global Peer GILEAD SCIENCES INC NASDAQ 85,751.867 15.720 31.843 4.1619 3.409
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 56,573.000 26.986 26.390 10.7688 -
Global Peer BIOGEN INC NASDAQ 52,730.566 11.901 9.773 3.7676 -
Global Peer ILLUMINA INC NASDAQ 47,123.790 57.051 48.431 10.6158 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 41,012.089 16.778 19.127 3.9043 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 25,815.821 81.695 24.104 5.4372 0.734
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,231.364 312.259 16.481 2.3373 -
Other Global Peers INCYTE CORPORATION (NASDAQ), SEATTLE GENETICS INC (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BLUEBIRD BIO INC (NASDAQ), REPLIGEN CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), GENSCRIPT BIO (HKEx), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), 3SBIO (HKEx), ALLOGENE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), HALOZYME THERAPEUTICS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ACCELERON PHARMA (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), XENCOR INC (NASDAQ), INSMED INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), ARVINAS INC (NASDAQ), EPIZYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), REGENXBIO INC (NASDAQ), VIELA BIO INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), VIR BIOTECHNOLOGY INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), VERACYTE INC (NASDAQ), NEXTCURE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), ROCKET PHARMACEUTICALS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), OPKO HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), LUMINEX CORP(DEL) (NASDAQ), INTREXON CORP (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), CORTEXYME INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), VIVA BIOTECH (HKEx), ACHILLION PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ASCENTAGE-B (HKEx), XBIOTECH INC (NASDAQ), KADMON HLDGS INC (NYSE), FLEXION THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), AVITA MEDICAL LTD (ASX), CARA THERAPEUTICS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), POLYNOVO LIMITED (ASX), AKEBIA THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), UROGEN PHARMA LTD (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), MESOBLAST LTD (ASX), SORRENTO THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), DERMIRA INC (NASDAQ), AVROBIO INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ARDELYX INC (NASDAQ), RETROPHIN INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), AGENUS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), SINOMAB BIO-B (HKEx), FREQUENCY THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MERUS B V (NASDAQ), MACROGENICS INC (NASDAQ), ASCLETIS-B (HKEx), SINOVAC BIOTECH LTD (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), ESSEX BIO-TECH (HKEx), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), PDL BIOPHARMA INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), BELLUS HEALTH INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), COMPUGEN (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), PERSONALIS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), GERON CORP (NASDAQ), CUE BIOPHARMA INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), SERES THERAPEUTICS (NASDAQ), LEE'S PHARM (HKEx), ELOXX PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), TELIX PHARMACEUTIC (ASX), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PFENEX INC (NYSE American), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), DPHARMA (Bursa), CHIASMA INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), NEXT SCIENCE LTD (ASX), XOMA CORP (NASDAQ), ATHERSYS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CABALETTA BIO INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), ARAVIVE INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BBI LIFE SCI (HKEx), FIVE PRIME THERAPEUTICS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), AVALON GLOBOCARE CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), IMV INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), ALDEYRA THERAPEUTICS (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), NANOVIRICIDES INC (NYSE American), FORTRESS BIOTECH INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), UNI-BIO GROUP (HKEx), LIMINAL BIOSCIENCES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), ENZO BIOCHEM INC (NYSE), AXOVANT GENE THERAPIES LTD (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), CHIMERIX INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), HARVARD BIOSCIENCE INC (NASDAQ), NOVAVAX INC (NASDAQ), VERASTEM INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), PARATEK PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ADURO BIOTECH INC (NASDAQ), IMUGENE LIMITED (ASX), 22ND CENTURY GROUP INC (NYSE American), SYNLOGIC INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), EQUILLIUM INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VERMILLION INC (NASDAQ), CEL-SCI CORP (NYSE American), COHBAR INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), CATALYST BIOSCIENCES INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), CURIS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), INMUNE BIO INC (NASDAQ), ORTHOCELL LIMITED (ASX), SAVARA INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CT ENTERPRISE (HKEx), RESTORBIO INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ORGENESIS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), PORT (SET), ARMATA PHARMACEUTICALS INC (NYSE American), NEON THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), SUNESIS PHARMACEUTICALS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), ISORAY INC (NYSE American), EVOGENE LTD (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), BIONOMICS LTD (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ZAFGEN INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), REGENT PACIFIC (HKEx), APTEVO THERAPEUTICS INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), BIOCARDIA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), ORAGENICS INC (NYSE American), MEMPHASYS LTD (ASX), SOLIGENIX INC (NASDAQ), CONTRAFECT CORP (NASDAQ), RHINOMED LIMITED (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), IBIO INC (NYSE American), BIOTRON (ASX), CORREVIO PHARMA CORP (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), INDIA GLOBALIZATION CAPITAL INC (NYSE American), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), PULMATRIX INCORPORATED (NASDAQ), TOCAGEN INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ATYR PHARMA INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), IMMURON LIMITED (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), ANTEOTECH LIMITED (ASX), DARE BIOSCIENCE INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), ADVAXIS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SENESTECH INC (NASDAQ), REGENEUS LTD (ASX), UNUM THERAPEUTICS INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), VAXART INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), GENETIC TECHNOLOGIES (ASX), PRECIPIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), OCUGEN INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CCP TECHNOLOGIES LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), BIOCEPT INC (NASDAQ), ADALTA LTD (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), TRILLIUM THERAPEUTICS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), TROVAGENE INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), BENITEC BIOPHARMA LTD (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), ARCA BIOPHARMA INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), MEGASUN (Bursa), REXAHN PHARMACEUTICALS INC (NASDAQ), MGRC (Bursa), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), HAO WEN HLDGS (HKEx), ENDRA LIFE SCIENCES INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), OPGEN INC (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), BPH ENERGY LIMITED (ASX), NANOLLOSE LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days ---
Medium Term Return 3 Months -+0.005
+1.69 %
6 Months -+0.135
+81.82 %
1 Year -+0.150
+100.00 %
Long Term Return 2 Years -+0.100
+50.00 %
3 Years -+0.168
+127.27 %
5 Years --0.425
-58.62 %
Annualised Return Annualised --
-16.18 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.100 - 0.300 Change From 1 Year Low +0.200 % Change From 1 Year Low (%) +200.00
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 0.100 - 0.300 Change From 2 Years Low +0.200 % Change From 2 Years Low (%) +200.00
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 0.100 - 0.800 Change From 5 Years Low +0.200 % Change From 5 Years Low (%) +200.00
Change From 5 Years High -0.500 % Change From 5 Years High (%) -62.50
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 22 September 2006 as a private limited company under the name Reyphon Agriceutical Pte Ltd. The Company was renamed to Reyphon Agriceutical Limited on 13 July 2007.
The Group's principal products are gibberellic acids, a plant growth regulator, and validamycin, a plant antibiotic. The Group also possess the know-how to produce fermentation-based pesticides. Its main product, gibberellic acids, is used in China mainly in the cultivation of hybrid rice, cotton, fruits and vegetables. Through active R&D, its objective is to widen the applications of gibberellic acids to cultivation of other plants such as tea plants, peanuts and soybean and lower its production costs and offer customers greater value with our gibberellic acids products.The Group manufactured, agriceutical products may be broadly classified into the following categories:-
(a) plant growth regulators;
(b) pesticides which include plant antibiotics, insecticide and weedicides; and
(c) fertilisers.

Its production facilities are located in Southern Industrial Development Zone of Xin?gan County, Jiangxi Province of China on a land area of approximately 65,002 sq m. Its products are sold throughout China such as Zhejiang, Fujian, Guangdong, Guangxi, Yunnan, Jiangsu, Shangdong, Hebei, Xinjiang, Anhui, Hainan, Hunan, Sichuan and Hubei. The Group also exports its products to countries such as United States, India, Turkey, Belgium, Canada, Germany, Malaysia, Pakistan, Spain, United Kingdom and Vietnam.

Change of Name:
Reyphon Agriceutical Limited to Suntar Eco-City Limited. Trading under the new name wef 14 June 2012.

Current core business of the Group has hereby expanded to include the eco-tourism real estate development and management business.

IPO Performance

Listing Date 01 Aug 2007 Full Subscription Rate (x) 13.55
No of Placement Shares (M) 76.60 No of Public Offer Shares (M) 2.00 Public Offer Subscription Rate (x) 494.05
IPO Price (SGD) a 1.950 First Day Close (SGD) a 3.050 First Week Close (SGD) a 2.500
Current vs IPO Price (%) -84.62 First Day Gain (%) +56.41 First Week Gain (%) +28.21
Notes:
  1. Adjusted for the following: Share Consolidation 1 for 5 on 19/11/2015

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(3.17 MB)
Annual Report 2017 Dec 2017 Part 1(4.01 MB)
Annual Report 2016 Dec 2016 Part 1(1.06 MB)
Annual Report 2015 Dec 2015 Part 1(1.97 MB)
Annual Report 2014 Dec 2014 Part 1(1.50 MB)
Annual Report 2013 Dec 2013 Part 1(0.95 MB)
Annual Report 2012 Dec 2012 Part 1(0.51 MB)
Annual Report 2011 Dec 2011 Part 1(0.64 MB)
Annual Report 2010 Dec 2010 Part 1(0.85 MB)
Annual Report 2009 Dec 2009 Part 1(0.98 MB)
Annual Report 2008 Dec 2008 Part 1(1.53 MB)
Annual Report 2007 Dec 2007 Part 1(1.61 MB)
IPO Prospectus
IPO Prospectus 2007 Jul 2007 Part 1(3.22 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
12 Dec 2019 0.300 0.300 0.300 0.300 - -
11 Dec 2019 0.300 0.300 0.300 0.300 - -
10 Dec 2019 0.300 0.300 0.300 0.300 - -
09 Dec 2019 0.300 0.300 0.300 0.300 - -
06 Dec 2019 0.300 0.300 0.300 0.300 - -
05 Dec 2019 0.300 0.300 0.300 0.300 - -
04 Dec 2019 0.300 0.300 0.300 0.300 - -
03 Dec 2019 0.300 0.300 0.300 0.300 - -
02 Dec 2019 0.300 0.300 0.300 0.300 - -
29 Nov 2019 0.300 0.300 0.300 0.300 - -
28 Nov 2019 0.300 0.300 0.300 0.300 - -
27 Nov 2019 0.300 0.300 0.300 0.300 10,000 0.3000
26 Nov 2019 0.300 0.300 0.300 0.300 20,000 0.3000
25 Nov 2019 0.300 0.300 0.300 0.300 800 0.3000
22 Nov 2019 0.300 0.300 0.300 0.300 - -
21 Nov 2019 0.300 0.300 0.300 0.300 3,000 0.3000
20 Nov 2019 0.300 0.300 0.300 0.300 - -
19 Nov 2019 0.300 0.300 0.300 0.300 - -
18 Nov 2019 0.300 0.300 0.300 0.300 61,800 0.3000
15 Nov 2019 0.300 0.300 0.300 0.300 - -
14 Nov 2019 0.300 0.300 0.300 0.300 - -
13 Nov 2019 0.300 0.300 0.300 0.300 - -
Summary
Current 2 Weeks
(29 Nov 2019 to 12 Dec 2019)
0.300 0.300 0.300 0.300 - -
Previous 2 Weeks
(15 Nov 2019 to 28 Nov 2019)
0.300 0.300 0.300 0.300 95,600 -
4 Weeks from
(17 Oct 2019 to 14 Nov 2019)
0.300 0.300 0.300 0.300 10,000 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.